MetaCap

ArriVent BioPharma (AVBP) vs Design Therapeutics (DSGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Design Therapeutics (DSGN) has outperformed ArriVent BioPharma (AVBP) over the past year, gaining 8.0% versus a loss of 48.3%. Design Therapeutics is the larger company by market cap ($577.6 million vs $544.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVBP-48.30%DSGN+8.02%
+98%+21%-55%
Nov 21, 20251 yearNov 20, 2026
AVBP-47.40%DSGN+283.83%
+596%+259%-78%
Jan 22, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVBP versus DSGN key metrics
MetricAVBPDSGN
Share price$10.52$9.02
Market cap$544.13M$577.61M
1-day change-6.57%-3.22%
YTD return-47.71%-3.84%
1-year return-48.30%+8.02%
5-year return—-49.27%
EPS (TTM)$-3.60$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-166.31M$-69.79M
52-week high$35.83$17.25
52-week low$10.33$8.21
Distance from 52-week high-70.64%-47.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+149.05%+139.14%
Average volume1.37M554.69K
Shares outstanding51.72M64.04M
Employees7760
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DSGN has outperformed AVBP by 56.3 percentage points over the past year.

About ArriVent BioPharma

AVBP stock →

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees

About Design Therapeutics

DSGN stock →

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

AVBP vs DSGN FAQ

Which is bigger, ArriVent BioPharma or Design Therapeutics?

Design Therapeutics (DSGN) is larger, with a market capitalization of $577.61M compared with $544.13M for ArriVent BioPharma (AVBP).

Which stock has performed better over the past year, AVBP or DSGN?

DSGN returned +8.02% over the past 12 months, compared with -48.30% for AVBP (price return, excluding dividends). Past performance does not predict future results.

Are ArriVent BioPharma and Design Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons